Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPME1 | Q9Y570 | 12/20 | 1.00 |
| ▸ | APEH | P13798 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16194669 | 1.00 | PPME1 (1.00) | PPME1APEHPKML3MBTL1MAPT | |
| SCHEMBL16194670 | 1.00 | PPME1 (1.00) | PPME1APEHPKML3MBTL1MAPT | |
| SCHEMBL29289251 | 0.72 | ALDH1A1 (0.60) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL29289250 | 0.72 | ALDH1A1 (0.60) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL11565020 | 0.69 | CYP1A2 (0.65) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL8425618 | 0.67 | PKM (0.51) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL8425615 | 0.67 | PKM (0.51) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL8425622 | 0.67 | PKM (0.51) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL29289216 | 0.66 | MAPT (0.55) | PPME1PKML3MBTL1MAPTKMT2A | |
| SCHEMBL29289213 | 0.66 | MAPT (0.55) | PPME1PKML3MBTL1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522174-A1 | MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCER | Syndax Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119464327-A | Pectin methylesterase gene involved in low methyl esterification pectin generation | 浙江大学 | 2025-02-18 | — | — | CN | disclosed |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| WO-2023220098-A1 | MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCER | SYNDAX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230100367-A1 | METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS | CHANG GUNG MEDICAL FOUNDATION, CHANG GUNG MEMORIAL HOSPITAL, LINKOU (TW) | 2023-03-30 | — | — | US | disclosed |
| WO-2023028117-A1 | METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS | YEH, TENG-KUANG (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-29 | — | — | US | disclosed |
| WO-2022251343-A2 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-01 | — | — | WO | disclosed |
| US-20200190592-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | Medical Diagnostic Laboratories, L.L.C. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10167472-B2 | PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170226520-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | Medical Diagnostic Laboratories, L.L.C. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9663789-B2 | PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9657349-B2 | PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150284723-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE ENDOMETRIAL AND BREAST CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140323546-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100367-A1 | METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS | CISD2, CISD1, DDHD2 | PPME1 2987/4885APEH 3525/4885PKM 3736/4885 |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | CISD2, CISD1, FECH | PPME1 3093/4885APEH 2834/4885PKM 3431/4885 |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | CISD2, CISD1, FECH | PPME1 3093/4885APEH 2834/4885PKM 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.